Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
Kuloglu
M
M
Caykoylu
A
A
Ekinci
O
O
Bayindirli
D
D
Vural
G
G
Deniz
O
O
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D017374:Paroxetine / Q000009:adverse effects*; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D018687:Antidepressive Agents, Second-Generation; D009025:Morpholines; D017374:Paroxetine; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors